Brian Reed: Hey. You see the LinkedIn post?
Eliza Ward: The DealShare one? Yeah, I did.
Brian Reed: Kamaldeep Singh announced he's leaving as CEO — October 2026, no explanation given. Just... out. While the company is actively in acquisition talks with TrueMeds.
Eliza Ward: That timing is — wait. Not before the talks started. Not after a deal closes. Right in the middle.
Brian Reed: And he's not going quiet somewhere. He's heading to Indofast Energy — the EV battery-swapping joint venture, Indian Oil Corporation and SUN Mobility. That's a very deliberate next move.
Eliza Ward: Okay but has anyone been named to replace him?
Brian Reed: No. No interim, no successor announced. Nothing.
Eliza Ward: So DealShare is mid-acquisition, leadership vacuum, and we're still figuring out what this actually means.
Brian Reed: And that vacuum is what makes the valuation story actually land. Because — let me think through this — Tiger Global and AlphaWave put in $165 million at a $1.7 billion valuation, January 2022. TrueMeds is now offering roughly $90 million. That's a 95% collapse in four years.
Eliza Ward: Right — but the part that breaks the headline is what that $90 million actually is.
Brian Reed: Yeah, what do you mean?
Eliza Ward: Think of it like selling a house that used to be worth $1.7 million. Except the offer you got is basically just — wait, here's the cleaner version — whoever's buying isn't paying for the house at all. They're absorbing the savings account sitting inside it. The $90 million is described as only marginally above DealShare's existing cash balance. So the operating business? The stores, the platform, whatever's left? That's trading for almost nothing.
Brian Reed: So TrueMeds isn't acquiring a company. They're acquiring a cash pile with some liabilities attached.
Eliza Ward: That's the salvage framing, yeah. And then you layer in FY25 — revenue fell 13.4% to Rs 432 crore. This isn't a distressed business that stabilized at a lower floor. It's still shrinking.
Brian Reed: And the retreat was already dramatic before that number. DealShare exited its entire B2B vertical in August 2023, pulled back from online operations, basically collapsed into whatever offline stores it had left. So the 432 crore is what survived after all that cutting.
Eliza Ward: Which means — actually, no, I'd push it further — the acquisition may not even be a choice at this point. If revenue is still declining post-restructuring, post-B2B exit, with no CEO... this might be the only exit before the cash itself starts going.
Brian Reed: Not a rescue. A salvage operation on something that's still deteriorating while the deal drags.
Eliza Ward: And that's the part where the 'advanced acquisition talks' framing really starts to fall apart.
Brian Reed: Yeah — that framing is doing a lot of work it hasn't earned. Because TrueMeds' own investors reportedly aren't uniformly aligned on this deal. That's not 'advanced.' That means you're still selling.
Eliza Ward: Right — advanced means both boards are locked in and you're arguing over mechanics. If one side's investors are fractured, you haven't even closed the selling phase yet.
Brian Reed: And then the question I can't actually answer — what is TrueMeds buying? Like, no source has cleanly articulated this. Is it the user base? The offline store leases? The logistics infrastructure, if any of that even still exists? Or are they just eliminating a distressed competitor and absorbing whatever customer data survives?
Eliza Ward: I don't have a clean answer either. And — wait, this is the part that makes me think TrueMeds might be the buyer of last resort. Captain Fresh was in acquisition discussions with DealShare earlier. They walked away. By September 2026, no longer active.
Brian Reed: Hold on. Captain Fresh — the meat and seafood company — was the prior bidder?
Eliza Ward: That's what the reporting shows. And they left. So TrueMeds isn't competing for DealShare — they're what's left after the more natural buyers decided it wasn't worth it.
Brian Reed: And then compound that with — all four co-founders gone by 2024. Rao, Bora, Medda, all out. Now Singh's gone. And CFO Ashish Shah is reportedly also considering leaving. So who is actually at the table negotiating this deal? That's the part we haven't gotten to yet — and honestly it might be the most broken piece of this whole thing.
Eliza Ward: No founders, no CEO, potentially no CFO. I mean — we don't know that this deal is dead. But 'advanced' is genuinely generous framing for what this looks like right now.
Brian Reed: And that vacuum has a body attached to it. Singh didn't just vanish — he landed somewhere very specific. Indofast Energy. EV battery-swapping, Indian Oil Corporation and SUN Mobility backing it. That's not a man who thinks he's leaving something recoverable.
Eliza Ward: Right — and the background matters there. He came to DealShare in December 2022 as president, became CEO January 2024. Nearly fifteen years at Big Bazaar before that, including a stint running it as CEO. The pitch was: here's someone who knows how to run value retail at scale.
Brian Reed: So he's the turnaround credential. And when the turnaround credential leaves for a forward-looking EV infrastructure role — I mean, that's him telling you something without saying it.
Eliza Ward: That's inference, to be fair. We don't actually know what he saw internally.
Brian Reed: No, we don't. But here's the practical problem — forget his reasons for a second. Who closes this deal? Like, imagine a TrueMeds lawyer needing a counterparty signature on a share-swap term sheet. Who picks up the phone? No CEO named. Ashish Shah, the CFO, reportedly also weighing leaving. The co-founders — Rao, Bora, Medda — all gone by 2024. There's no one with institutional authority left who — wait, is there even a board functioning at this point?
Eliza Ward: That's genuinely unanswered. The loss trajectory tells you everything — FY23, DealShare lost over Rs 500 crore on nearly Rs 1,963 crore in revenue. By FY25, losses narrowed to Rs 87.7 crore. But only because the business already shrank to Rs 432 crore in revenue. You didn't fix the model. You just ran it smaller until it bled less.
Brian Reed: A smaller fire isn't a fixed fire.
Eliza Ward: No. And TrueMeds has to know that. Picture whoever's doing diligence on their side — they're pulling FY25 numbers, they see the shrink, they look for the CEO contact to ask follow-up questions, and there's... no one there. That's when a counterparty starts asking whether this deal even has a functional close.
Brian Reed: Leadership erosion becoming its own dealbreaker. That feels like the concrete thing to watch — not the valuation math, not investor alignment. Whether TrueMeds can even find a counterparty capable of executing closing conditions before the cash situation forces a different outcome entirely.
Eliza Ward: Singh's departure reads completely differently depending on one outcome. If TrueMeds actually closes — if the share-swap completes — then he's someone who saw the finish line, handed it off, moved on. Clean. Rational. If the deal stalls or collapses, then October 2026 is the moment the last experienced operator walked out of a leaderless shell.
Brian Reed: And we genuinely don't know which one it is. I mean — the investor misalignment on TrueMeds' side, that's the concrete obstacle right now, not the valuation math. That's the thing worth watching.
Eliza Ward: Exactly — that's what I'm watching. Not whether the $90 million number moves. Whether TrueMeds' own investors get into alignment. Because until that's resolved, the deal isn't advanced. It's just... pending in a way that looks bad.
Brian Reed: And if it falls apart — actually, I keep thinking about Ashish Shah. The CFO. If he leaves too, then who manages the cash burn while nothing closes? That's not abstract. That's people on payroll waiting on someone to make a call.
Eliza Ward: We don't know yet. That's the honest answer.
